AT-MSCs Antifibrotic Activity is Improved by Eugenol through Modulation of TGF-β/Smad Signaling Pathway in Rats
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
For hepatic failure, stem cell transplantation has been chosen as an alternative therapy, especially for mesenchymal stem cells (MSCs). The aim of this study was to investigate the effect of eugenol (EUG) on the in vivo antifibrotic activity of adipose tissue-derived MSCs (AT-MSCs) and the underlying mechanism. After characterization of MSCs, rats were divided into five groups, Group 1 (normal control), Group 2 (CCl4), Group 3 (CCl4 + AT-MSCs), Group 4 (CCl4 + EUG) and Group 5 (CCl4 + AT-MSCs + EUG). Biochemical and histopathological investigations were performed. Furthermore, expression of type 1 collagen, α-SMA, TGF-β1, Smad3 and P-Smad3 was estimated. Compared to the single treatment with AT-MSCs, the combination treatment of the fibrotic rats with AT-MSCs and EUG significantly improved the plasma fibrinogen concentration, IL-10 level and proliferating cell nuclear antigen expression, and also significantly decreased the serum levels of liver enzymes, IL-6, IL-1β, TNF-α, type III collagen, hyaluronic acid, hydroxyproline and the TGF-β growth factor. Furthermore, the combination treatment significantly decreased the hepatic expression of fibrotic markers genes (Type 1 collagen and α-SMA) and proteins (α-SMA, TGF-β1 and phospho-Smad3) more than the treatment with AT-MSCs alone. We demonstrated that the combination treatment with EUG and AT-MSCs strongly inhibited the advancement of CCl4-induced hepatic fibrosis, compared with AT-MSCs alone, through TGF-β/Smad pathway inhibition. This approach is completely novel, so more investigations are necessary to improve our perception of the underlying molecular mechanisms accountable for the effects of EUG on the antifibrotic potential of AT-MSCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nowadays, researchers have increasingly demonstrated that combining MSC-based therapies with drugs, such as simvastatin, eugenol, imatinib, Juzentaihoto, Ferulic acid, and fucoxanthin, can improve the intervention efficacy in animal models [377–382].”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [377]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Kern, S., Eichler, H., Stoeve, J., Klüter, H., & Bieback, K. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0342 · Cited by 3,370
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842 · cited 1×
“If inappropriately handled, hepatic fibrosis may proceed to cirrhosis, resulting in patients requiring hepatic transplantation [11,12].”
BackgroundRemmele, W., & Stegner, H.-E. (1987) · PubMed · Cited by 1,976
Mesenchymal Stem Cells as Therapeutics
Parekkadan, B., & Milwid, J. M. (2010) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-070909-105309 · Cited by 759 · cited 1×
“MSCs also present many other features, like no adverse reactions related to MSCs transplant, and long-term storage without considerable loss of potency [4].”
BackgroundTGF-β in progression of liver disease
Dooley, S., & ten Dijke, P. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1246-y · Cited by 718
Kharaziha, P., Hellström, P. M., Noorinayer, B., Farzaneh, F., Aghajani, K., Jafari, F., Telkabadi, M., Atashi, A., Honardoost, M., Zali, M. R., et al. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832a1f6c · Cited by 492 · cited 2×
“uring the past fe years, researchers have reported that S s counter and exert therapeutic benefits against hepatic fibrosis [18,19].”
BackgroundTerai, S., Ishikawa, T., Omori, K., Aoyama, K., Marumoto, Y., Urata, Y., Yokoyama, Y., Uchida, K., Yamasaki, T., Fujii, Y., et al. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0542 · Cited by 491
Cytokine interactions in mesenchymal stem cells from cord blood
LIU, C., & HWANG, S. (2005) · Cytokine · doi:10.1016/j.cyto.2005.11.003 · Cited by 211
Strategies for anti-fibrotic therapies
Rosenbloom, J., Mendoza, F. A., & Jimenez, S. A. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.12.007 · Cited by 170
Cited by
The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy
Li, J., Wu, Z., Zhao, L., Liu, Y., Su, Y., Gong, X., Liu, F., & Zhang, L. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03587-y · Cited by 150
Alaaeldin, R., Abdel-Rahman, I. A. M., Hassan, H. A., Youssef, N., Allam, A. E., Abdelwahab, S. F., Zhao, Q.-L., & Fathy, M. (2021) · Molecules · doi:10.3390/molecules26247629 · Cited by 92
“Natural agents exhibited many in vitro [31,32] and in vivo [33,34] pharmacological actions in various disorders like carcinogenesis, [35] fibrosis, [36,37] angiogenesis, [38] and immunomodulation [39].”
BackgroundSelf-citationShokravi, S., Borisov, V. V., Zaman, B. A., Niazvand, F., Hazrati, R., Khah, M. M., Thangavelu, L. P., Marzban, S., Sohrabi, A. D., & Zamani, A. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02825-z · Cited by 73
“Adipose tissue Rat MSCs plus Eugenol Enhancing antifibrotic competencies of MSCs by eugenol through down-regulation of TGF-β/Smad axis [205]”
BackgroundCytokinins: Wide-Spread Signaling Hormones from Plants to Humans with High Medical Potential
Fathy, M., Eldin, S. S., Naseem, M., Dandekar, T., & Othman, E. M. (2022) · Nutrients · doi:10.3390/nu14071495 · Cited by 56
Self-citationRecent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis
Jangra, A., Kothari, A., Sarma, P., Medhi, B., Omar, B. J., & Kaushal, K. (2022) · Cells · doi:10.3390/cells11091500 · Cited by 58
Metadata
- Authors
- Fathy, M., Okabe, M., Saad Eldien, H. M., & Yoshida, T.
- Affiliations
- University of Toyama (JP)
- Department of Anatomy, College of Medicine, Jouf University, Jouf 74311, Saudi Arabia
- Corresponding author
- Yoshida, Toshiko
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-01-15
- Volume
- 25
- Issue
- 2
- Pages
- 348
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7024200
- OpenAlex
- W3000324902
- Cited by
- 44
- References
- 31
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 10 · 2023: 9 · 2022: 10 · 2021: 7 · 2020: 3
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (20K12642)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- adipose-derived stem cells, eugenol, antifibrotic activity, liver fibrosis, TGF-β/Smad signaling, Smad3 phosphorylation, carbon tetrachloride-induced liver injury, combination therapy, type I collagen, alpha-smooth muscle actin, inflammatory cytokines, fibrinogen
- MeSH terms
- Animals, Anti-Infective Agents, Carbon Tetrachloride, Eugenol, Liver Cirrhosis, Male, Signal Transduction, Transforming Growth Factor beta, Rats, Sprague-Dawley, Mesenchymal Stem Cell Transplantation, Rats, Smad Proteins, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AT-MSCs Antifibrotic Activity is Improved by Eugenol through Modulation of TGF-β/Smad Signaling Pathway in Rats. https://app.cochat.ai/papers/10.3390/molecules25020348
- The paper
- Fathy, M., Okabe, M., Saad Eldien, H. M., & Yoshida, T. (2020). AT-MSCs Antifibrotic Activity is Improved by Eugenol through Modulation of TGF-β/Smad Signaling Pathway in Rats. Molecules. https://doi.org/10.3390/molecules25020348
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.